Another example of a biotech once left for dead and now successful. You don't need to read this article or care about their drug (not relevant to IPIX) to understand the chart.

Article

https://endpts.com/focused-on-its-2nd-commerc...givosiran/

Chart

http://bigcharts.marketwatch.com/quickchart/q...mp;time=20

By the way, they have a 9.3 Billion market cap, are not profitable, are projected to lose money again this year (lots of money), and just had a mixed-result clinical trial -- results were good but bad side effects.

They have one approved drug, which their 2nd drug might replace. It is for a rare disease.

So, a 9.3 Billion market cap for a company that is unlikely to affect as many patients as Brilacidin-OM would reach.

IPIX market cap is just under 26 Million.

Efficient markets, what a laugh.